Short- and long-term follow-up outcomes of patients with Brucella endocarditis: a systematic review of 207 Brucella endocarditis Cases

Figures & data

Figure 1. Study selection flow diagram

BE, Brucella endocarditis

Figure 2. The trend of publication distribution between 1970 and 2019

Table 1. The basic information of Brucella endocarditis patients

Parameters	Value/n	Percentage(%)
Median age(years)(n = 207)	45(35–52)
Sex(n = 207) Male Female	155 52	74.9 25.1
Risk factors(n = 132) Unpasteurized dairy consumption Animal contact only Unpasteurized dairy + Animal contact	72 51 9	34.8 24.6 4.3
Underlying cardiac condition(n = 145) Aortic valve insufficiency Rheumatic heart disease Aortic stenosis Bicuspid aortic valve Prosthetic valve Mitral valve insufficiency Mitral stenosis Pacemaker placement	45 36 12 10 10 8 6 5	70.0 21.7 17.4 5.8 4.8 4.8 3.9 2.9 2.4
Treatment(n = 205) Combined surgical and medical therapy Medical therapy only	179 26	86.5 12.6
Blood culture (n = 176) Positive Negative	114 62	55.1 30.0
Infecting strain(n = 134) B. melitensis B. abortus B. suis B. canis	120 10 3 1	58.0 4.8 1.4 0.5
Valve style(n = 201) Native valve Prosthetic valve	171 30	82.6 14.5
Involved valve(n = 205) AV MV AV + MV Pacemaker AV + MV + TV ASD TV Laboratory examination ESR↑ CRP↑ Titer(n = 164) <1:320 ≥1:320 ≥1:640 ≥1:1280 Vegetations ≥10 mm	120 41 35 4 1 3 1 123 59 16 78 24 46 163 30	58.0 19.8 16.9 2.0 0.5 1.4 0.5 59.4 28.5 7.7 37.7 11.6 22.2 78.7 14.5
Complications(n = 97) Abscess Embolic event Renal complication Pulmonary complications Arrhythmia Spondylitis Paravalvular leak Neurobrucellosis Other Heart failure Event rate (n = 17) ≤6 months >6 months	28 13 12 9 5 5 4 2 19 115 3 14	46.9 13.5 6.2 5.8 4.3 2.4 2.4 1.9 1.0 9.2 55.6 11.1 8.2

AV aortic valve, _BV mitral valve, TV Tricuspid valve, ASD Atrial Septal Defect, ESR erythrocyte sedimentation rate, CRP C-reactive protein

Figure 3. The country-based distribution of patients with Brucella endocarditis

Table 2. Multivariate Binary logistic regression analysis of influencing factors for follow-up outcomes

Indicators	Odds Ratio	P value	95% CI
Age 40–59 Age ≥ 60	0.277 0.323	0.011 0.165	0.103–0.748 0.065–1.594
Medical treatment	0.404	0.404	0.048–3.400
Heart failure Prosthetic valve	2.467 0.277	0.104 0.232	0.830–7.331 0.034–2.273
AV involved MV involved	0.479 0.407	0.225 0.274	0.145–1.575 0.081–2.038

AV aortic valve, BV mitral valve